Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 4:46 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 457–480 of 661 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Seizure Clear all
Completed Phase 3 Interventional Results available

Trial to Assess Long-term Lacosamide (LCM) Monotherapy Use and Safety of LCM Monotherapy and Adjunctive Therapy for Partial-onset Seizures

NCT00530855
View directory record Official record
Conditions
Epilepsy
Interventions
Lacosamide
Drug
Lead sponsor
UCB Pharma
Industry
Eligibility
16 Years to 70 Years
Enrollment
322 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
77
States / cities
Alabaster, Alabama • Birmingham, Alabama • Northport, Alabama + 66 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2018 · Synced Oct 23, 2026, 4:46 AM EDT
Recruiting Not applicable Interventional

A Multi-site Feasibility Clinical Trial of Retraining and Control Therapy (ReACT), a Mind and Body Treatment for Pediatric Functional Seizures

NCT05819268
View directory record Official record
Conditions
Functional Seizures, Convulsion, Non-Epileptic
Interventions
ReACT, CATCH-IT
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
11 Years to 18 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Oct 23, 2026, 4:46 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Crossover Bioequivalence Study of Oxcarbazepine 600 mg Suspension Under Fed Conditions

NCT01703468
View directory record Official record
Conditions
Seizures
Interventions
Oxcarbazepine
Drug
Lead sponsor
Roxane Laboratories
Industry
Eligibility
18 Years to 45 Years
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Oct 23, 2026, 4:46 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

SeizEAR Safety Study

NCT07088835
View directory record Official record
Conditions
Epilepsy
Interventions
SeizEAR
Device
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 70 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 23, 2026, 4:46 AM EDT
Terminated Phase 4 Interventional

Effectiveness Study Comparing Treatment With Drug(s) or Adjunctive VNS Therapy for Pharmacoresistant Partial Seizures

NCT00215215
View directory record Official record
Conditions
Epilepsies, Partial
Interventions
Vagus Nerve Stimulation Therapy
Device
Lead sponsor
Cyberonics, Inc.
Industry
Eligibility
12 Years and older
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
23
States / cities
Phoenix, Arizona • Sun City, Arizona • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2006 · Synced Oct 23, 2026, 4:46 AM EDT
Recruiting Not applicable Interventional

FITting Non-invasive Tests in Lynch Syndrome Surveillance

NCT06898996
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Fecal immunochemical test
Other
Lead sponsor
University of Chicago
Other
Eligibility
20 Years to 80 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
3
States / cities
Chicago, Illinois • Ann Arbor, Michigan • New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 23, 2026, 4:46 AM EDT
Completed Not applicable Interventional Results available

Fitting Strategy Study

NCT04972162
View directory record Official record
Conditions
Hearing Loss, Sensorineural
Interventions
Web App Strategy Fitting, Standard-of-care Fitting
Device
Lead sponsor
WSAUD A/S
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Vermillion, South Dakota
Source: ClinicalTrials.gov public record
Updated Sep 30, 2025 · Synced Oct 23, 2026, 4:46 AM EDT
Completed Phase 3 Interventional Results available

Open-label Long-term Study of Adjunctive Brivaracetam in Pediatric Subjects With Epilepsy

NCT01364597
View directory record Official record
Conditions
Epilepsy
Interventions
Brivaracetam (BRV)
Drug
Lead sponsor
UCB Pharma SA
Industry
Eligibility
28 Days to 17 Years
Enrollment
257 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2022
U.S. locations
15
States / cities
Los Angeles, California • Gulf Breeze, Florida • Wellington, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Oct 23, 2026, 4:46 AM EDT
Completed Phase 3 Interventional Results available

Phase 3 Study of Adjunctive Ganaxolone in Adults With Drug-resistant Partial Onset Seizures and Open-label Extension

NCT01963208
View directory record Official record
Conditions
Drug Resistant Partial Onset Seizure
Interventions
ganaxolone, Placebo
Drug
Lead sponsor
Marinus Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
405 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
33
States / cities
Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 25 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2023 · Synced Oct 23, 2026, 4:46 AM EDT
Completed No phase listed Observational

Evaluation of StatNet Device for Electroencephalogram (EEG) Recordings

NCT03103425
View directory record Official record
Conditions
Epilepsy, Seizures
Interventions
Not listed
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 6, 2017 · Synced Oct 23, 2026, 4:46 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Risk Factors for Sudden Unexplained Death in Epilepsy

NCT01662453
View directory record Official record
Conditions
SUDEP
Interventions
Not listed
Lead sponsor
NYU Langone Health
Other
Eligibility
Not listed
Enrollment
800 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 23, 2026, 4:46 AM EDT
Completed Phase 4 Interventional Results available

Antiepileptic Drugs and Osteoporotic Prevention Trial

NCT00869622
View directory record Official record
Conditions
Epilepsy, Bone Loss, Osteoporosis, Fractures
Interventions
Risedronate, Placebo + Calcium and Vitamin D
Drug
Lead sponsor
Boston VA Research Institute, Inc.
Other
Eligibility
18 Years to 85 Years · Male only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 24, 2015 · Synced Oct 23, 2026, 4:46 AM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Safety and Efficacy of USL261 in Patients With Increased Bouts of Seizure Activity in the EMU

NCT01999777
View directory record Official record
Conditions
Epilepsy
Interventions
USL261, Placebo
Drug
Lead sponsor
UCB Biopharma S.P.R.L.
Industry
Eligibility
12 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
37
States / cities
Phoenix, Arizona • Tucson, Arizona • La Jolla, California + 34 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2019 · Synced Oct 23, 2026, 4:46 AM EDT
Recruiting Not applicable Interventional

Non-Invasive Low Intensity Focused Ultrasound Stimulation for Drug-Resistant Epilepsy

NCT07680842
View directory record Official record
Conditions
Drug-Resistant Epilepsy, Epilepsy, Epilepsy (Treatment Refractory), Epilepsy Comorbidities, Epilepsy, Drug Resistant, Epilepsy, Generalized, Epilepsy, Focal
Interventions
Target optimization using LIFU, Serial LIFU stimulation
Device
Lead sponsor
University of California, San Francisco
Other
Eligibility
21 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Oct 23, 2026, 4:46 AM EDT
Completed Phase 1 Interventional Results available

University of Alabama at Birmingham (UAB) Pediatric CBD Program

NCT02695537
View directory record Official record
Conditions
Epilepsy, Seizures
Interventions
Epidiolex
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
1 Year to 19 Years
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Apr 10, 2020 · Synced Oct 23, 2026, 4:46 AM EDT
Completed Phase 3 Interventional

Dose Response Study of Zonegran in Patients With Newly Diagnosed Epilepsy

NCT00056576
View directory record Official record
Conditions
Epilepsy, Complex Partial
Interventions
Zonisamide
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
16 Years and older
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
25
States / cities
Birmingham, Alabama • Huntsville, Alabama • Northport, Alabama + 22 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2011 · Synced Oct 23, 2026, 4:46 AM EDT
Completed Not applicable Interventional

Medium Chain Triglycerides as an Adjunct to the Modified Atkins Diet for Women With Catamenial Epilepsy

NCT02426047
View directory record Official record
Conditions
Epilepsy, Seizure, Catamenial Epilepsy, Medically Resistant Epilepsy, Medically Resistant Seizures
Interventions
betaquik®
Dietary Supplement
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older · Female only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
2
States / cities
Baltimore, Maryland • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 15, 2020 · Synced Oct 23, 2026, 4:46 AM EDT
Completed Phase 3 Interventional Results available

This Trial, Evaluating the Long-term Safety and Tolerability of Brivaracetam Will Provide Subjects Suffering From Epilepsy, Who May Have Benefited From Brivaracetam as Adjunctive Treatment, the Opportunity to Receive Open Label Brivaracetam Treatment

NCT00150800
View directory record Official record
Conditions
Epilepsy
Interventions
Brivaracetam
Drug
Lead sponsor
UCB PHARMA Inc. (US)
Industry
Eligibility
16 Years and older
Enrollment
668 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2017
U.S. locations
46
States / cities
Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 38 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2021 · Synced Oct 23, 2026, 4:46 AM EDT
Terminated Not applicable Interventional Results available

Repeated TMS at Low Frequencies to Reduce Seizure Occurrence

NCT03154307
View directory record Official record
Conditions
Epilepsy, Status Epilepticus, Epilepsia Partialis Continua, Epilepsia Partialis Continua, Refractory (Medically)
Interventions
Low frequency repeated TMS (LF-rTMS)
Device
Lead sponsor
Baptist Health South Florida
Other
Eligibility
18 Years to 80 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 23, 2023 · Synced Oct 23, 2026, 4:46 AM EDT
Completed Phase 1 Interventional

An Open-Label Interaction Study to Look at the Effects of Brivaracetam on Phenytoin When Taken Together in 15 Adult Patients With Epilepsy.

NCT00426673
View directory record Official record
Conditions
Epilepsy
Interventions
Brivaracetam (ucb34714)
Drug
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
3
States / cities
Little Rock, Arkansas • Charlottesville, Virginia • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 10, 2008 · Synced Oct 23, 2026, 4:46 AM EDT
Completed Phase 4 Interventional Results available

1 Week Versus 6 Weeks of Levetiracetam in Surgical Brain Tumor Patients

NCT02334722
View directory record Official record
Conditions
Brain Neoplasms, Brain Cancer, Brain Tumors, Cancer of the Brain, Cancer of Brain, Seizure
Interventions
Levetiracetam
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Dec 15, 2021 · Synced Oct 23, 2026, 4:46 AM EDT
Completed Phase 4 Interventional Results available

IV Keppra in the Emergency Department for Prevention of Early Recurrent Seizures

NCT00510783
View directory record Official record
Conditions
Tonic-clonic Seizure
Interventions
Keppra, Fosphenytoin, Dilantin
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 12, 2013 · Synced Oct 23, 2026, 4:46 AM EDT
Completed Not applicable Interventional

Ketogenic Diet for Child Epilepsy and Seizure Control

NCT00004729
View directory record Official record
Conditions
Epilepsy, Seizures, Lennox-Gastaut Syndrome
Interventions
Ketogenic diet
Behavioral
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
1 Year to 10 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 22, 2006 · Synced Oct 23, 2026, 4:46 AM EDT
Completed Phase 3 Interventional Results available

An Open-Label Extension Trial to Assess the Long-Term Safety of ZX008 (Fenfluramine Hydrochloride HCl) Oral Solution in Children and Young Adults With Dravet Syndrome

NCT02823145
View directory record Official record
Conditions
Dravet Syndrome
Interventions
ZX008 (Fenfluramine Hydrochloride)
Drug
Lead sponsor
Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.
Industry
Eligibility
2 Years to 35 Years
Enrollment
375 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
24
States / cities
Phoenix, Arizona • Tucson, Arizona • Orange, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2025 · Synced Oct 23, 2026, 4:46 AM EDT